Clinical Trial: A Prospective, Multicenter Phase II Clinical Study of Zanubrutinib in Combination with Sonrotoclax as a Chemotherapy-Free Targeted Therapy in Patients with Treatement-naive CLL/SLL Based on TP53 Risk Stratification (China)

Posted On: 2026-08-31

China, Aug. 31 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective, Multicenter Phase II Clinical Study of Zanubrutinib in Combination with Sonrotoclax as a Chemotherapy-Free Targeted Therapy in Patients with Treatement-naive CLL/SLL Based on TP53 Risk Stratification'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131015

Registration Time: 2026/08/27

Type: Interventional study

Primary Sponsor: West China Hospital of Sichuan University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=334201

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: A Prospective, Multicenter Phase II Clinical Study of Zanubrutinib in Combination with Sonrotoclax as a Chemotherapy-Free Targeted Therapy in Patients with Treatement-naive CLL/SLL Based on TP53 Risk Stratification (China)